We are a therapeutics company leveraging human milk biology to create new medicines to transform gut-brain axis (GBA) disorders with large populations underserved by current treatment options. Our initial drug candidates are based on bioactive oligosaccharides naturally produced in human milk, or HMOs, which directly modulate the immune system and other human cells, as well as the gut microbiome.
We believe our synthetic biology-manufactured human milk oligosaccharide, or HMO, drug candidates have the potential to affect multiple pathways implicated in GBA disorders and certain inflammatory disorders, while reproducing the favorable safety and tolerability profile observed of HMOs. We are prioritizing the development of our drug candidates for disorders where available treatment options are inadequately serving people living with GBA disorders due to safety or tolerability issues and where we have the potential to redefine the standard of care.
Human Milk Oligosaccharide Based Medicines
Human milk oligosaccharides (HMOs) are the largest non-nutrient, bioactive component of human milk• Comprising 200+ oligosaccharides, this abundance and diversity is not found in other mammals.
Our HMO-based medicines are identical to their equivalent HMOs, each of which possesses distinct bioactivity• We are elucidating the immunological and microbiome benefits of distinct synthetic HMOs to develop as targeted new medicines for distinct gut-brain axis disorders.
Our Oligosaccharide Medicines (OMs) are synthetic biology produced HMOs• Only recently, through synthetic biology, have individual HMO-equivalent OMs been produced at a scale sufficient for the therapeutic development of these molecules in gold-standard clinical trials and potential commercialization to be feasible.
CEO, Chairman & Co - Founder
COO, President & Co - Founder
MB BS, (Syd), FRACP, Chief Medical Officer
General Counsel, Senior Vice President, Legal and Corporate Development, and Corporate Secretary